{
  "ticker": "EZZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959888",
  "id": "02959888",
  "pages": 12,
  "price_sensitive": false,
  "date": "20250619",
  "time": "0823",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwqm59fj7bgr.pdf",
  "summary": "**Summary of Material Information (Investor Presentation):**  \n\n- **Financial Highlights (Q1-Q3 FY25):**  \n  - Receipts from customers: **$45.8M** (+4% YoY).  \n  - Operating cash flow: **$2.9M** (+73% YoY).  \n  - Cash balance: **$21.1M** (no external debt).  \n  - Gross margin: **77%** (as of 31 Dec 2024).  \n  - Interim dividend: **2 cents per share**.  \n\n- **Expansion Updates:**  \n  - **Southeast Asia:** Signed **3-year distribution deal** with ROFA Enterprises ($21M minimum purchase commitment); entry into Thailand, Vietnam, and Singapore.  \n  - **US Market:** Launched *EZZ Day* brand (4 SKUs), secured FDA registration, and commenced local manufacturing. Shopify store live; Amazon launch imminent.  \n\n- **Distribution Growth:**  \n  - Added **14 new pharmacy stores**; total reach: **600+ chemists, 200+ retailers, 750+ e-commerce platforms**.  \n\n**No capital raising, trading halt, or material structural changes identified.**  \n\n*Note: Excludes forward-looking statements, disclaimers, and non-material operational details.*",
  "usage": {
    "prompt_tokens": 2040,
    "completion_tokens": 270,
    "total_tokens": 2310,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T22:49:00.010286"
}